CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pharmena SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pharmena SA
ul. Gdanska 47/49
Phone: +48 422807707p:+48 422807707 LODZ, 90-729  Poland Ticker: PHRPHR
This company was Merged or Acquired on 12/27/2016.
This is a Subsidiary, click here for the Parent Company
Business Summary
Pharmena SA is a Poland-based pharmaceutical and life science company specializing in the research, development, and commercialization of products and technologies derived from scientific research, particularly in the areas of healthy aging, bioscience, and topical technologies. The Company is structured around research and development activities focused on the biological and therapeutic potential of 1-methylnicotinamide (1-MNA), a naturally occurring metabolite of niacin, and develops dietary supplements, health-related products, and drug candidates based on this technology. The Company's core activity centers on the application of 1-MNA technology, including products marketed under the Endotelio and Menavitin product lines. The Company conducts research in cooperation with academic institutions and research centers and supports its activities through patent protection and commercialization of developed technologies in domestic and international markets.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
2833 Medicinal chemicals and botanical products
2836 Biological products, except diagnostic substances
2844 Perfumes, cosmetics, and other toilet preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Management Board, Chief Executive Officer KonradPalka
Vice Chairman of the Management Board, Director of Research and Development MarzenaWieczorkowska 4/1/2008 4/1/2008
Chief Accounting Officer KatarzynaKonopacka
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Pharmena SA
PHR

General Information
Number of Employees: 7 (As of 12/31/2025)
Outstanding Shares: 11,137,758 (As of 6/30/2026)
Stock Exchange: WAR
Fax Number: +48 422913371


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 14, 2026